PTC Therapeutics shared the below letter to the Duchenne community. We are pleased to see the results of the dystrophin study (Study 045) and thankful for PTC’s longtime commitment to […]
CureDuchenne’s webinar, COVID-19 Vaccines: What the Duchenne Community Needs to Know, was an opportunity for the Duchenne community to get reliable information on COVID-19 vaccines. A panel of experts from […]
NEWPORT BEACH, Calif., Jan. 14, 2021 – CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, announces a new initiative centered on the COVID-19 vaccine rollout […]
CureDuchenne is pleased to share news that Avidity Biosciences has announced exciting details of its Duchenne program today, the full press release is below. CureDuchenne Ventures made an investment in […]
— Study met the primary biological endpoint of micro-dystrophin protein expression at 12 weeks post-treatment, as measured by western blot, in SRP-9001-treated participants versus placebo — — SRP-9001-treated participants showed […]
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 CIFFREO study, which will evaluate the efficacy and safety of investigational […]
– Pivotal program for RGX-314, potential best-in-class, one-time gene therapy for the treatment of wet AMD, is active and expected to support BLA filing in 2024— Recently completed an End […]
Newport Beach, CA, December 21, 2020 – CureDuchenne, a leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, announced today a new initiative to deliver […]
Dear Committee Members, On behalf of individuals living with Duchenne muscular dystrophy, their families, and caregivers served by CureDuchenne, I am writing to urge the Committee to include individuals with Duchenne in its recommendations for sub-populations to receive approved or authorized COVID-19 […]
